ARTICLE | Clinical News
AT-406: Phase II started
June 13, 2016 7:00 AM UTC
Debiopharm began a double-blind Phase II trial of oral Debio 1143 plus carboplatin and paclitaxel. Debiopharm has exclusive, worldwide rights from Ascenta to develop and commercialize Debio 1143 (see ...